Dusigitumab
Based on 1 Customer Validation
Dusigitumab is a fully human IgG2λ monoclonal antibody that targets IGF-1 and IGF-2 with picomolar binding affinity. Dusigitumab blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R as well as activation of IR-A, thereby inhibiting the activation of downstream signaling pathways. Dusigitumab is applicable to research related to advanced solid tumors and hormone receptor-positive metastatic breast cancer.
For research use only. We do not sell to patients.
- Purity: 96.37%
- CAS No.: 1204390-13-5
- Molecular Weight:144.24 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG2 lambda
Human
IGF-1&IGF-2
P01344-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 lambda
ELISA, FACS, Functional assay
-
Immobilized IGF-I/IGF-1 Protein, Human can bind Dusigitumab. The EC50 for this effect is 145.7 ng/mL. -
Flow cytometric analysis of 1X106 HepG2 cells with Dusigitumab (HY-P99867, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 lambda (HY-P991206, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1204390-13-5
-
Appearance Liquid
-
Molecular Weight 144.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Dusigitumab]
-
Synonyms
MEDI 573
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. de Bono J, et al. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer. 2020;122(9):1324-1332. [Content Brief]
[2]. Osher E, et al. Therapeutic Targeting of the IGF Axis. Cells. 2019;8(8):895. Published 2019 Aug 14. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)